Entrada Therapeutics (TRDA) Non-Current Assets (2020 - 2026)

Entrada Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $68.6 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 17.58% year-over-year to $68.6 million; the TTM figure through Mar 2026 stood at $294.0 million (down 16.28% YoY), while the FY2025 annual figure was $71.1 million, down 17.57% from the prior year.
• Non-Current Assets was $68.6 million for Q1 2026 at Entrada Therapeutics, down from $71.1 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $103.8 million in Q2 2023 to a low of $39.7 million in Q3 2022.
• Historically, Non-Current Assets has averaged $73.9 million across 5 years, with a median of $79.6 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets surged 491.35% in 2022, then slipped 17.58% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $42.2 million in 2022, then jumped by 135.7% to $99.4 million in 2023, then slipped by 13.22% to $86.3 million in 2024, then retreated by 17.57% to $71.1 million in 2025, then dropped by 3.49% to $68.6 million in 2026.
• The last three Non-Current Assets figures came in at $68.6 million (Q1 2026), $71.1 million (Q4 2025), and $74.6 million (Q3 2025), per Business Quant data.